Cargando…
Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer
BACKGROUND: Health technology assessment (HTA) is currently one of the major challenges in assessing medical innovations and healthcare systems. In Europe, the European Network for Health Technology Assessment (EUnetHTA) has been aspiring to develop and implement standards for international sharing...
Autores principales: | Kiselova Bilekova, Beata, Gavurova, Beata, Rogalewicz, Vladimír |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755544/ https://www.ncbi.nlm.nih.gov/pubmed/30349986 http://dx.doi.org/10.1186/s13561-018-0211-9 |
Ejemplares similares
-
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016) -
Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017) -
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017) -
Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)